Gilead Sciences, Inc.
NEWS
BMS accused Kite and Gilead of copying the research conducted at Memorial Sloan Kettering to push the development of Yescarta.
Earlier this week, an HIV-prevention advocacy group, PrEP4All Collaboration, filed a petition with the U.S. Patent and Trademark Office (PTO) alleging that Gilead Sciences intentionally delayed the development of a safer HIV drug.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
HHS stated that Gilead had “willfully and deliberately induced infringement of the HHS patents.” As a result, “Gilead has profited from research funded by hundreds of millions of taxpayer dollars and reaped billions from PrEP,” through the sale of Truvada and Descovy.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
A disappointed Merck said it was reviewing its options for a possible appeal, while a pleased Gilead said if an appeal came, it was confident a higher court would come to the same verdict as the federal appeals court.
Despite the success Gilead Sciences has seen with its JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.
JOBS
IN THE PRESS